The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary embolism - Venous thrombosis/thromboembolism
Publications
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Journal of drugs in dermatology : JDD 2009 Aug;8;765-9 — 2009 Aug — 765-9
Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.
International journal of hematology 2008 Jun;87;542-544 — 2008 Jun — 542-544
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
JAMA 2006 Dec 06;296;2558-60 — 2006 Dec 06 — 2558-60
Thalidomide therapy and deep venous thrombosis in multiple myeloma.
Mayo Clinic proceedings 2005 Dec;80;1549-51 — 2005 Dec — 1549-51
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.
British journal of haematology 2003 Apr;121;101-3 — 2003 Apr — 101-3
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Cancer 2002 Oct 15;95;1629-36 — 2002 Oct 15 — 1629-36